Infectious Disease · PANCE / PANRE

Kawasaki Disease

Self-limited medium-vessel vasculitis of young children; principal threat is coronary artery aneurysms; treated with IVIG and aspirin within 10 days of fever onset.

Also known as: mucocutaneous lymph node syndrome, MCLS, Kawasaki syndrome, infantile polyarteritis

Overview

An acute, self-limited febrile vasculitis of medium-sized arteries that predominantly affects children under 5. Cardinal feature is fever ≥5 days with at least four of: bilateral non-exudative conjunctivitis, oral mucosal changes, extremity changes, polymorphous rash, and unilateral cervical lymphadenopathy. Untreated, 20-25% develop coronary artery aneurysms.

Epidemiology

Highest incidence in children of Asian (especially Japanese) descent; ~6,000 US cases/year. 80% of cases in children <5 years. Slight male predominance. Peak in late winter and spring. Etiology unknown, presumed infectious trigger in a genetically predisposed host.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Kawasaki Disease outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Age <5 years
  • Asian (especially Japanese, Korean) ancestry
  • Male sex
  • Sibling with prior Kawasaki disease
  • MIS-C following SARS-CoV-2 has overlapping features but is a distinct entity

Pathophysiology

Postulated infectious trigger initiates an immune cascade in genetically susceptible children, leading to medium-vessel vasculitis with prominent coronary artery involvement. Activated T cells, macrophages, and cytokine surge produce endothelial dysfunction and arterial wall edema, weakening and dilating affected vessels.

Clinical presentation

Symptoms

  • Fever ≥5 days, often 39-40 °C, unresponsive to antipyretics
  • Bilateral non-exudative conjunctival injection with limbic sparing
  • Lip changes: red, dry, cracked, fissured; strawberry tongue
  • Extremity changes: erythema and edema of palms and soles in week 1; periungual desquamation in week 2-3
  • Polymorphous rash: morbilliform, scarlatiniform, or erythema multiforme-like; perineal accentuation in infants
  • Unilateral cervical lymphadenopathy ≥1.5 cm
  • Irritability disproportionate to exam, especially infants

Signs / physical exam

  • Tachycardia disproportionate to fever
  • BCG site reactivation (red, indurated) where BCG given
  • Hydrops of gallbladder, sterile pyuria, arthritis, aseptic meningitis can occur

Classic findings

Cracked red lips, strawberry tongue, red palms and soles, bilateral conjunctivitis, and a polymorphous rash in a febrile irritable toddler.

Differential diagnosis

  • Scarlet fever — Strep pharyngitis with sandpaper rash; lacks extremity changes and conjunctivitis
  • Measles — Three Cs and Koplik spots; cephalocaudal rash
  • Stevens-Johnson syndrome — Mucosal involvement with sloughing and target lesions, drug exposure
  • Staphylococcal or streptococcal toxic shock — Hypotension and end-organ failure; toxin-mediated
  • Multisystem inflammatory syndrome in children (MIS-C) — Recent SARS-CoV-2 exposure, older children, more cardiac dysfunction and shock; overlaps significantly with Kawasaki
  • Juvenile idiopathic arthritis (systemic) — Quotidian fevers, salmon rash, arthritis; ferritin extremely high
  • Adenovirus — Exudative conjunctivitis (vs non-exudative in KD); shorter fever course

Diagnostic workup

Diagnostic criteria

Classic Kawasaki: fever ≥5 days plus ≥4 of 5 principal features (conjunctivitis, lip/oral changes, extremity changes, rash, cervical adenopathy). Incomplete Kawasaki: fever ≥5 days with 2-3 features plus supportive labs and/or coronary changes.

Labs

  • CBC: leukocytosis with left shift in week 1, thrombocytosis (>450,000) classically appears in week 2
  • ESR and CRP elevated; persistent elevation supports diagnosis
  • LFTs: mild transaminitis, hypoalbuminemia
  • Urinalysis: sterile pyuria
  • BNP/NT-proBNP often elevated
  • Echocardiogram at diagnosis, 1-2 weeks, and 4-6 weeks — assess coronary artery dimensions (z-scores)
  • Consider SARS-CoV-2 testing (PCR and antibody) to distinguish from MIS-C in current era

Imaging

  • Transthoracic echocardiogram is mandatory and serial
  • ECG to detect arrhythmias and ischemia
  • Cardiac MRI or coronary CT for follow-up of aneurysms

Diagnostic algorithm

flowchart TD
  A[Fever ≥5 days<br/>young child] --> B{≥4 of 5 features?<br/>conj / lips / extremities<br/>rash / cervical node}
  B -->|Yes| C[Classic Kawasaki]
  B -->|2-3 features| D[Incomplete Kawasaki<br/>check CRP/ESR + echo]
  D -->|Supportive| C
  C --> E[IVIG 2 g/kg + high-dose ASA<br/>within 10 days]
  E --> F{Fever resolves<br/>≤36 h?}
  F -->|Yes| G[Low-dose ASA<br/>+ serial echo]
  F -->|No| H[IVIG-resistant:<br/>repeat IVIG ± steroids<br/>± infliximab]
  G --> I{Coronary aneurysm?}
  I -->|Small| J[Continue low-dose ASA]
  I -->|Large/giant| K[ASA + anticoagulation<br/>lifelong cardiology follow-up]
Kawasaki disease diagnostic and treatment algorithm.

Treatment

First-line

  • IVIG + ASA for Kawasaki — IVIG 2 g/kg as a single infusion over 10-12 hours within 10 days of fever onset (and ideally before day 7)
  • High-dose aspirin 30-50 mg/kg/day in 4 divided doses until afebrile for 48-72 hours, then low-dose aspirin 3-5 mg/kg/day until inflammatory markers and coronary imaging normalize
  • Continue low-dose aspirin if coronary aneurysms develop; add anticoagulation (warfarin, LMWH) for large or giant aneurysms

IVIG-resistant Kawasaki

  • Persistent or recurrent fever ≥36 hours after IVIG
  • Re-treat with second IVIG 2 g/kg
  • Adjunctive corticosteroids (methylprednisolone pulse or prednisolone taper) for high-risk patients (Kobayashi score)
  • Infliximab or cyclosporine as third-line

Late presentation (>10 days)

  • Treat with IVIG if persistent fever, ongoing inflammation, or coronary changes
  • Aspirin and serial echocardiography

Second-line / adjunct

  • Live vaccines (MMR, varicella) should be delayed 11 months after IVIG (passive antibody interferes with the live-vaccine immune response); inactivated influenza vaccine is unaffected and need not be deferred
  • Avoid live MMR/varicella for 11 months after IVIG

Complications

  • Coronary artery aneurysms (giant aneurysm = z-score >10 or >8 mm) with risk of thrombosis, stenosis, MI, and sudden death
  • Myocarditis, pericarditis, valvular regurgitation
  • Arrhythmias
  • Long-term: premature atherosclerosis, even without persistent aneurysm
  • Hepatitis, gallbladder hydrops, sterile pyuria, aseptic meningitis (typically self-limited)

PANCE pearls

  • Fever ≥5 days with at least four principal features — start IVIG within 10 days to reduce aneurysm rate from 20-25% to ~3-5%.
  • Periungual desquamation in week 2-3 is a retrospective clue but cannot wait — diagnose and treat early on fever and other features.
  • Aspirin is one of the few pediatric indications that overrides Reye-syndrome avoidance; benefits outweigh risks here.
  • Defer live vaccines (MMR, varicella) for 11 months after IVIG.
  • Incomplete Kawasaki is more common in infants and requires supportive labs plus echo to support diagnosis.

References

  • AHA 2017 — AHA Scientific Statement: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease (McCrindle et al., Circulation 2017;135:e927-e999)
  • AAP Red Book — American Academy of Pediatrics Red Book — Kawasaki Disease

Practice Infectious Disease questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.